Protagonist Therapeutics, Inc. (PTGX) Financials

PTGX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 885.5 million 44.0 million
March 31, 2026 697.5 million 42.0 million
Dec. 31, 2025 669.9 million 55.2 million
Sept. 30, 2025 701.7 million 56.3 million

PTGX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 218.9 million 14.0 million
March 31, 2026 -49.2 million 14.5 million
Dec. 31, 2025 -35.5 million 10.7 million
Sept. 30, 2025 -2.0 million 10.6 million

PTGX Net Income

No data available :(

PTGX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 782.6 million - 9.2 million
March 31, 2026 547.8 million - 9.8 million
Dec. 31, 2025 567.4 million - 8.0 million
Sept. 30, 2025 576.1 million - 8.5 million

PTGX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 71.0 million
March 31, 2026 70.5 million
Dec. 31, 2025 63.6 million
Sept. 30, 2025 63.8 million

PTGX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 168000 42.1 million 12.6 million -
March 31, 2026 215000 46.7 million 13.3 million -
Dec. 31, 2025 1.4 million 46.4 million 11.4 million -
Sept. 30, 2025 88000 40.0 million 11.1 million -

PTGX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 213.5 million -
March 31, 2026 56.4 million 407000
Dec. 31, 2025 7.4 million 376000
Sept. 30, 2025 4.7 million -

PTGX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

PTGX

Price: $155.10

52 week price:
50.49
155.10

Earnings Per Share: 1.04 USD

P/E Ratio: 140.26

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 966400

Ebitda: -4.9 million

Market Capitalization: 9.4 billion

Links: